Stifel Nicolaus Begins Coverage on Palvella Therapeutics (NASDAQ:PVLA)

Research analysts at Stifel Nicolaus initiated coverage on shares of Palvella Therapeutics (NASDAQ:PVLA) in a note issued to investors on Wednesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $45.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 65.02% from the company’s current price.

PVLA has been the topic of a number of other reports. Canaccord Genuity Group restated a “buy” rating and set a $39.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Scotiabank assumed coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective on the stock. Jones Trading initiated coverage on Palvella Therapeutics in a research note on Tuesday. They set a “buy” rating and a $45.00 target price for the company. TD Cowen initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They issued an “overweight” rating on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Palvella Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $43.50.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA opened at $27.27 on Wednesday. The company’s 50-day simple moving average is $19.36. The stock has a market cap of $306.00 million, a PE ratio of -2.25 and a beta of 0.54. Palvella Therapeutics has a 12-month low of $6.20 and a 12-month high of $29.27.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PVLA. BML Capital Management LLC purchased a new position in Palvella Therapeutics during the fourth quarter worth $506,000. Geode Capital Management LLC purchased a new position in Palvella Therapeutics in the 4th quarter valued at about $171,000. ADAR1 Capital Management LLC acquired a new stake in shares of Palvella Therapeutics during the 4th quarter worth about $1,736,000. Renaissance Technologies LLC acquired a new position in shares of Palvella Therapeutics in the fourth quarter valued at approximately $256,000. Finally, Blue Owl Capital Holdings LP purchased a new position in shares of Palvella Therapeutics during the fourth quarter valued at approximately $3,001,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.